Drug Profile
Research programme: melanocortin 4 receptor agonists - Palatin Technologies/AstraZeneca
Alternative Names: PT 15Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator AstraZeneca; Palatin Technologies
- Developer Palatin Technologies
- Class Antihyperglycaemics; Metals; Obesity therapies; Peptides; Small molecules
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Metabolic syndrome; Obesity
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 28 Apr 2022 No recent reports of development identified for preclinical development in Metabolic-syndrome in USA
- 28 Apr 2022 No recent reports of development identified for preclinical development in Obesity in USA